Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult1/2. fázis

Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease

A legfontosabb adatok

Ki végzi
Lingyi Biotech Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
1/2. fázis
Résztvevők
18 fő, tervezett
Kezdés
2026. jún. 15.
Várható befejezés
2032. dec. 30.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • LY-M003 Injection
A regiszteradat frissítve
2026. július 2.

Ki vehet részt

The trial is looking for adults with Wilson's disease who are already on standard treatment. They get a single dose of the gene therapy LY-M003 Injection.

Életkor
18 Years to 60 Years
Nem
All sexes
A betegség stádiuma
Confirmed Wilson's disease. People with decompensated cirrhosis or advanced liver disease, or a MELD score > 13, cannot join.
Korábbi kezelés
At least 6 months of standard therapy (for example D-penicillamine or zinc acetate) and at least 6 months of a low-copper diet before screening. No earlier gene therapy or cell therapy.
Biomarker vagy leletérték
Lab test showing a biallelic ATP7B gene mutation or deletion (both copies of the gene changed or missing). AAV8 neutralizing antibody titer must not be > 1:10.
A részvétel fő kizáró okai
  • Decompensated liver cirrhosis or advanced liver disease, or other liver diseases
  • Positive test for hepatitis B, hepatitis C, HIV or syphilis
  • Kidney disease on dialysis, or creatinine clearance < 60 mL/min
  • Past or planned bone marrow, stem cell or organ transplant
  • Pregnant or breastfeeding women, or women planning pregnancy
A regiszter összes feltétele (33)A regiszter feltételeinek elrejtése

Ki vehet részt

  • The subject fully comprehends the purpose, design, methods and possible adverse events of the study, agrees to participate voluntarily and signs the informed consent form (ICF)
  • Patients with confirmed diagnosis of Wilson's disease (WD)
  • Subjects with Wilson's disease (WD) confirmed by laboratory testing to have biallelic ATP7B gene mutation or deletion
  • The subjects are treated patients with Wilson's disease (WD) who have received standard therapy (e.g., D-penicillamine or zinc acetate) continuously for at least 6 months prior to screening
  • Subjects have maintained a low-copper diet for at least 6 consecutive months prior to screening and will continue this dietary restriction throughout the study
  • Subjects must agree to refrain from donating blood, organs, tissues or cells at any time after treatment
  • Female subjects of childbearing potential (WOCBP) must have a negative pregnancy test
  • Subjects and their partners must have no plans for pregnancy from screening through 6 months after study completion, and will voluntarily use effective contraception (e.g., abstinence, condoms). Subjects shall not plan to donate sperm or ova

Ki nem vehet részt

  • AAV8 neutralizing antibody titer > 1:10
  • Subjects with other concomitant liver diseases as judged by the investigator, including autoimmune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug- or toxin-induced liver disease
  • A history of non-compliance with copper chelators or zinc agents as assessed by the investigator within 6 months prior to screening
  • Subjects who have received or plan to undergo bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation and renal transplantation
  • Subjects with uncontrolled concomitant diseases or infectious diseases as assessed by the investigator
  • Prior receipt of any type of gene therapy or cell therapy
  • Use of systemic immunosuppressants or steroids within 3 months prior to administration (except for prophylactic immunosuppressive therapy specified in the protocol)
  • Received live attenuated vaccines within 4 months prior to screening, or planned to receive such vaccines during the clinical trial
  • Received treatment or intervention with other investigational drugs or study devices within 28 days or 5 half-lives (for drugs only) prior to screening, whichever is longer
  • History of active gastrointestinal bleeding within the past 3 months
  • Decompensated liver cirrhosis or advanced liver disease presenting with portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc
  • Model for End-Stage Liver Disease (MELD) score > 13
  • Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc
  • Subjects with positive hepatitis B surface antigen (HBsAg), positive hepatitis C virus (HCV) antibody, positive human immunodeficiency virus (HIV) antibody or positive treponema pallidum antibody
  • Subjects with clinically diagnosed severe cardiovascular diseases or those deemed by the investigator to have such conditions (e.g., New York Heart Association [NYHA] heart failure classification ≥ Class 3)
  • Subjects who are allergic to any ingredient of LY-M003 Injection
  • History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer and fully cured ductal carcinoma in situ
  • Other conditions that, in the investigator's opinion, render the subject ineligible for study participation
  • Previously treated WD subjects with ALT and/or AST levels more than 5 times the upper limit of normal (ULN)
  • Hemoglobin < 90g/L
  • Subjects with end-stage renal disease on dialysis (Chronic Kidney Disease Stage 3 and above), or creatinine clearance < 60 mL/min
  • Severe hyperlipidemia (triglycerides >1000 mg/dL)
  • Subjects with severe hypersplenism complicated and requiring splenectomy as assessed by the investigator
  • Subjects with severe neurological deficits or impairments that, in the investigator's judgment, compromise their safety and/or ability to participate in the study
  • Pregnant women (or women planning pregnancy) or breastfeeding women

Alkalmassági kérdőív

Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.

  • Életkor
  • Wilson's disease

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-M003 Injection in patients with Wilson's Disease (WD).

A vizsgálat 3 csoportja

  • Phase 1: LY-M003 Dose group 1A vizsgált kezelés

    Kezelés: LY-M003 Injection

  • Phase 1: LY-M003 de-escalation doseA vizsgált kezelés

    Kezelés: LY-M003 Injection

  • Phase 2: LY-M003 Dose group 1A vizsgált kezelés

    Kezelés: LY-M003 Injection

Következő lépések

Az orvosodnak

Kérdőlap az orvosnak

PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.

A PDF letöltése

PDF, US Letter, 1–2 oldal. A4 méretben

A vizsgálati csapatnak

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Open, Single-arm, Single-dose, Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT07641140: ki vehet részt
A regiszteradat frissítve
2026. július 2.